Submitted by Joseph Calhoun via Alhambra Investment Partners,
All that we see or seem is but a dream within a dream.
Edgar Allan Poe
All things are subject to interpretation. Whichever interpretation prevails at a given time is a function of power not truth.
Friedrich Nietzsche
I was walking down the street wearing glasses when the prescription ran out.
Steven Wright
I think one of the hardest […]
Calm was seemingly restored last week as Greece embraced a punishing deal offered by the EU while Chinese authorities reversed the A-share meltdown with a capital infusion estimated at over $200 billion dollars and the implied threat of capital punishment for anyone daring to sell short. Against a backdrop of positive economic releases and a pullback from catastrophe overseas, a […]
Just over a year ago, Janet Yellen did the unthinkable. In a moment of clarity, The Fed called out two darlings of the momentum-chasing euphoria-driven stock buying frenzy for ‘special’ treatment when Yellen uttered the Cramer-mind-blowing fact that “small cap social media and biotech stock valuations were substantially stretched.” It appears, judging by today’s market, that she was half right…The […]
The market staged another strong recovery this week as the SP500 regained its 20 WMA after briefly dipping below the last couple weeks. How quickly this market responds is a testament to why sticking to the long-term trends and keeping an open mind are so beneficial for proper money management. During this most recent “meltdown” (where the SP500 declined only […]
“Bubble” can be a provocative word in investing circles. Think of all that comes to mind when you hear it — perhaps other words like over-hyped, overvalued, risky, etc. To quote from our own Motley Fool investing wiki, a bubble “occurs when people are happily paying more for stocks in a certain sector than they are worth given the fundamentals […]
With biotech stocks leaping again this week, a number of market watchers are predicting that this highflying sector is set to tumble back to earth.
But other investors remain upbeat. Former Lehman Brothers trader Jared Dillian writes over at Mauldin Economics that it “hasn’t been fun” for the traders who “have tried for years to short biotech.”
“Like tech in the ‘90s […]
7-1-15Secular Market Top – Since January 2000+53.3% Dow+171.8% Transports+94.2% Utilities+40.4% S&P 500+22.5% Nasdaq+52.2% 30yr Treasury Bond+304.6% Gold+132.3% OilFrom High to Low+304.6% Gold+171.8% Transports+132.3% Oil+94.2% Utilities+53.3% Dow Jones+52.2% 30 Year Treasury+40.4% S&P 500+22.5% NasdaqIt is easily seen that in the year 2000 the Nasdaq was horribly overvalued and gold was on the give away table, such lopsided returns 15 years later!Here […]
By Johanna BennettDo you want safe, or sexy?That’s the question facing biotechnology investors, according to a recent research note from Cowen analysts that previews the sector’s second-quarter financial results.“In heady times, large cap provides a safe haven, smid caps the sex appeal,” reads the note.After shrugging off a selloff in late June, the Nasdaq Biotechnology index has gained 30% since […]
By Johanna BennettDo you want safe, or sexy?That’s the question facing biotechnology investors, according to a recent research note from Cowen analysts that previews the sector’s second-quarter financial results.“In heady times, large cap provides a safe haven, smid caps the sex appeal,” reads the note.After shrugging off a selloff in late June, the Nasdaq Biotechnology index has gained 30% since […]
by Joshua Brown, The Reformed BrokerThe pendulum always swings too far in both directions. I would tell you the ratio of passive fund inflows to active fund inflows over the last few years but I can’t because the latter category would be a negative integer.Instead, I’ll just tell you that almost 100 cents of every dollar has gone into index […]
